CoChat

Risedronate in the Treatment of Paget's Disease of Bone: An Open Label, Multicenter Study

Siris, Ethel S., Chines, Arkadi A., Altman, Roy D., Brown, Jacques P., Johnston, C Conrad, Lang, Robert, Mcclung, Michael R., Mallette, Lawrence E., Miller, Paul D., Ryan, Will G., Singer, Frederick R., Tucci, Joseph R., Eusebio, Rachelle A., Bekker, Pirow J. · 1998 · Journal of Bone and Mineral Research
Cited by 142

The DOI matches its Crossref record.

Abstract

An open-label, multicenter study was conducted to determine the efficacy and safety of oral risedronate (a pyridinyl bisphosphonate) in 162 patients (102 men, 60 postmenopausal women; mean age, 68 years) with moderate to severe Paget's disease of bone (mean serum alkaline phosphatase [ALP] approximately seven times the upper limit of normal). Patients were treated with oral risedronate, 30 mg/day for 84 days, followed by 112 days without treatment. This 196-day cycle was repeated once if serum ALP did not normalize or increased from the nadir value by ≥25%. At the end of the first and second cycles, the mean percentage decreases for serum ALP were 65.7% and 69.1%, and for urinary hydroxyproline/creatinine 50.4% and 66.9%, respectively. The decreases from baseline in ALP and urinary hydroxyproline/creatinine were significant (p < 0.001). Normalization of serum ALP was observed in 86 patients (53.8%): 53 during the first treatment cycle and 33 during the second. There was a significant proportion of patients reporting a decrease in the pagetic bone pain at days 84 and 196 (p < 0.001). Overall, risedronate was well tolerated. Five patients withdrew due to adverse events, none of which were considered to be drug related. In conclusion, 30 mg of oral risedronate administered daily for 84 days significantly reduced the biochemical indices of disease activity and was associated with pain reduction in patients with moderate to severe Paget's disease of bone. Normalization of ALP was observed in the majority of patients. Repeated administration of risedronate was shown to be beneficial. In general, risedronate was well tolerated and demonstrated a good safety profile.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1359/jbmr.1998.13.6.1032

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 142

Metadata

Authors
Siris, E. S., Chines, A. A., Altman, R. D., Brown, J. P., Johnston, C. C., Lang, R., Mcclung, M. R., Mallette, L. E., Miller, P. D., Ryan, W. G., Singer, F. R., Tucci, J. R., Eusebio, R. A., & Bekker, P. J.
Venue
Journal of Bone and Mineral Research
Published
1998-06-01
Volume
13
Issue
6
Pages
1032-1038
ISSN
  • 0884-0431 (ISSN-L)
  • 1523-4681
OpenAlex
W1987690548
Cited by
142
References
0
FWCI
6.19
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risedronate in the Treatment of Paget's Disease of Bone: An Open Label, Multicenter Study. https://app.cochat.ai/papers/10.1359/jbmr.1998.13.6.1032
The paper
Siris, E. S., Chines, A. A., Altman, R. D., Brown, J. P., Johnston, C. C., Lang, R., Mcclung, M. R., Mallette, L. E., Miller, P. D., Ryan, W. G., Singer, F. R., Tucci, J. R., Eusebio, R. A., & Bekker, P. J. (1998). Risedronate in the Treatment of Paget's Disease of Bone: An Open Label, Multicenter Study. Journal of Bone and Mineral Research. https://doi.org/10.1359/jbmr.1998.13.6.1032

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.